An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women
NCT05038878 is a phase 4 interventional trial sponsored by Icahn School of Medicine at Mount Sinai. As of 21 Nov 2026, it was terminated. It studies Elagolix in Mild Autonomous Cortisol Excess. The registry lists an enrollment of 4 participants at 1 site in 1 country. The registry lists a start date of 6 Jul 2021 and a primary completion date of 24 Jun 2022.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT05038878 |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional trial |
| Lead sponsor | Icahn School of Medicine at Mount Sinai |
| Enrollment | 4 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Mild Autonomous Cortisol Excess |
| Drugs | Elagolix |
| Start | 6 Jul 2021 |
| Primary completion | 24 Jun 2022 |
| Study completion | 24 Jun 2022 |
| Last update posted | 18 Mar 2025 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Alice C Levine
Icahn School of Medicine at Mount Sinai
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Icahn School of Medicine at Mount Sinai
New York
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT05038878
Each answer restates registry values shown on this page.
What is NCT05038878?
NCT05038878 is a phase 4 interventional trial sponsored by Icahn School of Medicine at Mount Sinai. It studies Elagolix in Mild Autonomous Cortisol Excess.
Who leads NCT05038878?
The registry names Alice C Levine (principal investigator, Icahn School of Medicine at Mount Sinai) as the overall official.
Where does NCT05038878 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT05038878 study?
The registered drug and biological interventions are Elagolix.
When did NCT05038878 end?
The registry lists a primary completion date of 24 Jun 2022 and a study completion date of 24 Jun 2022. The sponsor last updated the record on 18 Mar 2025.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.